

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- ✓ • BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

★ASTR B02 96-171368/17 ★WO 9607400-A1  
Ramipril and dihydro:pyridine calcium antagonist - used in solid unit dose compsn. for treatment of systolic hypertension, minimises coughing, peripheral oedema and flushing (Eng)

ASTRA AB 94.09.02 94SE-002925 (94.09.02 94SE-002924)

(B03) (96.03.14) A61K 9/22, 31/44, 38/05

95.08.30 95WO-SE00972 N(AM AT AU BB BG BR BY CA CH  
CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ  
LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT  
RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN) R(AT  
BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT  
SD SE SZ UG)

A pharmaceutical compsn. for oral administration comprises a combination of: (a) the ACE inhibitor ramipril or one of its salts; and (b) a dihydropyridine cpd. selected from felodipine, nitrendipine, nifedipine and lacidipine and their salts. (a) is in instant release form, (b) is in extended release (ER) form and the combination is in solid fixed unit dosage form.

USE - The compsn. is partic. effective in the treatment of systolic hypertension.

ADVANTAGE - The choice of an instant release form of (a) and an extended release form of (b) both contribute to the optimal use of both drugs, minimising adverse side-effects while still being effective against elevated blood pressure. The adverse effects of (a) i.e. coughing, and (b), i.e. peripheral oedema and flushing, are minimised. (37pp Dwg.No.0/3)

CT: 2.Jnl.Ref CA2070085 EP265685 US5178867

C96-054023

8/10 WPIL - (C) Derwent

AN - 1996-171368 [17]

TI - Ramipril and dihydro:pyridine calcium antagonist - used in solid unit dose compsn. for treatment of systolic hypertension, minimises coughing, peripheral oedema and flushing

PA - (ASTR) ASTRA AB

PN - WO9607400 A1 19960314 DW1996-17 A61K-009/22 Eng 37p \*

AP: 1995WO-SE00972 19950830

DSNW: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP  
KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD  
SE SG SI SK TJ TM TT UA UG US UZ VN  
DSRW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ  
UG

- MX9601586 A1 19980101 DW1999-52 A61K-009/22

AP: 1996MX-0001586 19960429

- NZ-292298 A 19980226 DW1998-13 A61K-009/24

FD: Based on WO9607400

AP: 1995NZ-0292298 19950830; 1995WO-SE00972 19950830

- SK9600558 A3 19970305 DW1997-29 A61K-009/22

AP: 1995WO-SE00972 19950830; 1996SK-0000558 19950830

- NO9601726 A 19960314 DW1996-46 A61K-031/44

AP: 1995WO-SE00972 19950830; 1996NO-0001726 19960429

- AU9534029 A 19960327 DW1996-27 A61K-009/22

FD: Based on WO9607400

AP: 1995AU-0034029 19950830

- FI9601863 A 19960502 DW1996-32 A61K-000/00

AP: 1995WO-SE00972 19950830; 1996FI-0001863 19960502

- JP09504806 W 19970513 DW1997-29 A61K-038/00 30p

FD: Based on WO9607400

AP: 1995WO-SE00972 19950830; 1996JP-0509416 19950830

- ZA9507043 A 19960529 DW1996-28 A61K-000/00 35p

AP: 1995ZA-0007043 19950822

- HUT076049 T 19970630 DW1998-07 A61K-009/22

FD: Based on WO9607400

AP: 1995WO-SE00972 19950830; 1996HU-0001146 19950830

- EP-726766 A1 19960821 DW1996-38 A61K-009/22 Eng

FD: Based on WO9607400

AP: 1995EP-0930771 19950830; 1995WO-SE00972 19950830

DSR: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

- AU-695865 B 19980827 DW1998-46 A61K-009/22

FD: Previous Publ. AU9534029; Based on WO9607400

AP: 1995AU-0034029 19950830

- CZ9601173 A3 19960911 DW1996-43 A61K-009/22

AP: 1996CZ-0001173 19950830

- BR1100047 A3 19970916 DW1997-44 A61K-009/22

AP: 1996BR-1100047 19960920

- CN1134665 A 19961030 DW1998-03 A61K-009/22

AP: 1995CN-0190823 19950830

**PCT**WORLD INTELLECTUAL PROP  
International B

INTERNATIONAL APPLICATION PUBLISHED UNDER



(51) International Patent Classification <sup>6</sup> : <b>A61K 9/22, 38/05, 31/44</b>		(11) Int. Pub. No. <b>WO 9607400A1</b>
<b>A1</b>		(43) International Publication Date: <b>14 March 1996 (14.03.96)</b>
(21) International Application Number: <b>PCT/SE95/00972</b>		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: <b>30 August 1995 (30.08.95)</b>		
(30) Priority Data: <b>9402924-6 2 September 1994 (02.09.94) SE</b> <b>9402925-3 2 September 1994 (02.09.94) SE</b>		
(71) Applicant (for all designated States except US): <b>ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</b>		
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>BAUER, Brigitte [DE/DE]; Ettesterstrasse 34, D-64291 Darmstadt (DE). KARLSSON, Christer [SE/SE]; Höganäsvägen 48, S-437 35 Lindome (SE). LUNDBERG, Per, Johan [SE/SE]; Torsgatan 6, S-431 38 Mölndal (SE). NILSSON, Berit [SE/SE]; Götabergsgatan 11, S-411 34 Göteborg (SE). SANDBERG, Anders [SE/SE]; Hökegårdsgatan 57, S-431 38 Mölndal (SE). SICKMÜLLER, Alfred [DE/DE]; Schweinfurter Weg 72, D-60599 Frankfurt am Main (DE).</b>		
(74) Agent: <b>ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</b>		<b>Published</b> <i>With international search report.</i>
(54) Title: <b>NOVEL PHARMACEUTICAL COMPOSITION CONTAINING THE ACE INHIBITOR RAMIPRIL AND A DIHYDROPYRIDINE COMPOUND</b>		
(57) Abstract <p>A pharmaceutical composition which is a combination of the ACE inhibitor ramipril and a calcium antagonist of one of the dihydropyridine type compounds felodipine, nitrendipine, nifedipine and lacidipine. The pharmaceutical composition is for use in the therapy and treatment of hypertension.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**NOVEL PHARMACEUTICAL COMPOSITION CONTAINING THE ACE INHIBITOR RAMIPRIL  
AND A DIHYDROPYRIDINE COMPOUND**

Field of the Invention

5 The present invention being a new pharmaceutical composition is related to a novel pharmaceutical preparation for oral administration and the use of this pharmaceutical preparation in the therapy of hypertension and of diseases in the cardiovascular system and secondary effects thereof in mammals including man. It is also related to compositions and to methods of preparing said pharmaceutical  
10 preparations. The pharmaceutical preparation is a fixed unit dosage form of the long-acting angiotensine converting enzyme (ACE) inhibitor, ramipril, in instant release form and a calcium antagonist of the dihydropyridine type i.e. a calcium channel blocking agent (dihydropyridine compound) in an extended release formulation.

15

The present invention also relates to solid preparations which are fixed combinations of the long acting ACE inhibitor ramipril in instant release form and a dihydropyridine compound such as the vascular selective drug felodipine in extended release form having the characteristic of achieving an effect over 24  
20 hours after once daily administration. The pharmaceutical preparations of the present invention retain a good therapeutic effect in the treatment of hypertension even when the active drugs are administered in low doses. The pharmaceutical preparations reduce the dose related adverse events which result from administering higher doses of each of the drugs separately. The pharmaceutical  
25 preparations of this invention simplify the regimen and improve patient compliance.

Background of the Invention

30 ACE inhibitors are compounds which inhibit the conversion of angiotensine I into

the active angiotensine II as well as the breakdown of the active vasodilator bradykinin. Both of these mechanisms lead to vasodilation. Such compounds have been described in, for example, EP 158927, EP 317878, US 4,743,450, and US 4,857,520. Ramipril (disclosed in EP 079022) is a long-acting ACE inhibitor. Its  
5 active metabolite is the free acid ramiprilat, which is obtained in vivo upon administration of ramipril. In hypertensive patients administration of ramipril is known to cause a reduction in peripheral arterial resistance and thus a reduction of the blood pressure without a compensatory rise in heart rate. It is being used in the treatment of hypertension and congestive heart failure. Furthermore, ramipril  
10 has been shown to reduce mortality in patients with clinical signs of congestive heart failure after surviving an acute myocardial infarction. Ramipril has been suggested to have an added advantage over many other ACE inhibitors due to its pronounced inhibition of ACE in tissues resulting in organ protective effects in e.g. the heart, lung, and kidney.

15

Ramipril substance is sensitive to high temperature, moisture or compression and therefore, upon formulation into pharmaceutical preparations needs special attention in order to retain its stability (US 5,151,433).

20 Calcium antagonists are compounds which influence the inflow of calcium ions into cells, in particular into the cells of smooth muscles. Such compounds of the dihydropyridine type have been described in, for example, GB 1358951 (nitrendipine), US 3,644,627 (nifedipine), EP 007293 (felodipine), and GB 2164336 (lacidipine).

25

The most common adverse events which are observed in clinical use of the ACE inhibitor and the calcium antagonists of this invention are headache, coughing, peripheral oedema, flush, dizziness, fatigue and nausea.

30 Some dihydropyridines, for example nifedipine and felodipine are decomposed

when exposed to light, and therefore, upon handling and formulation into pharmaceutical preparations need special attention in order to retain their stability.

Combinations of ACE inhibitors and calcium antagonists of dihydropyridine type  
5 in the treatment of hypertension have been described in, for example EP 488059,  
EP 180785 and EP 265685.

Bainbridge, A.D. et al. (Br.J. Clin. Pharmac. 1993, 36: 323-330) have studied the  
use of the angiotensin converting enzyme inhibitor ramipril and an extended  
10 release formulation of the dihydropyridine calcium channel antagonist felodipine  
given in free combination as separate dosage forms.

In US 4,703,038 solid combinations for oral administration of certain ACE  
inhibitors and certain dihydropyridine compounds including i.a. nitrendipine and  
15 felodipine are described. This document also describes a method of treating  
hypertension in man using such combinations. US 4,703,038 does not, however,  
disclose ramipril as an ACE inhibitor. Neither does it describe the use of extended  
release formulations of dihydropyridines.

20 In US 5,236,933 the use of combinations of certain ACE inhibitors including i.a.  
ramipril, and certain calcium antagonists, i.a. felodipine have been described in  
the prevention and/or treatment of proteinuria.

#### Description of the Invention

25

The term "instant release" as used herein defines the release of an active drug  
component that conforms with the criteria in USP XXII under entry "<711>  
Dissolution" when Q=75%, the time interval is 60 minutes and the dissolution  
medium is the one specified in the Examples 5-8 below.

30

The term "extended release" as used herein defines the dissolution of the active drug component from the dosage form over an extended period of time, i.e. for more than 6 hours as measured with the testing method described in Examples 5-8 below.

5

The term "fixed unit dosage form" as used herein defines a physical embodiment containing more than one active drug component, which embodiment has a heterogenous structure.

- 10 Dose figures of pharmaceutically acceptable salts of the active drug given herein relate to the amount of the corresponding free base or acid.

The present invention provides a solid, fixed unit dosage form for oral administration, for example a tablet or a capsule, of an instant release formulation  
15 of the long acting ACE inhibitor ramipril or a pharmaceutically acceptable salt of ramipril, and an extended release preparation of a dihydropyridine selected from the group consisting of felodipine, nitrendipine, nifedipine, and lacidipine or a pharmaceutically acceptable salt thereof. Said solid, fixed unit dosage form is effective and tolerable after once daily dosing. Most preferred of the  
20 dihydropyridines is felodipine or a pharmaceutically acceptable salt thereof. The choice of an instant release formulation of the long acting ACE inhibitor ramipril and an extended release preparation of a dihydropyridine both contribute to the optimal use of both drugs thereby minimizing the adverse effects while still being effective against elevated blood pressure.

25

The molecule corresponding to ramipril has five chiral centers and can, thus, occur in 32 different enantiomeric forms. The enantiomer with the name (2S,3aS,6aS)-1-[N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-octahydro-cyclopenta[b]pyrrol-2-carboxylic acid is preferred. This compound is called

30

ramipril.



Pharmaceutically acceptable salts of ramipril are, for example, salts with pharmaceutically acceptable amines or inorganic or organic acids such as, for example, HCl, HBr, H<sub>2</sub>SO<sub>4</sub>, maleic acid, fumaric acid, tartaric acid and citric acid.

5

Felodipine has one chiral center and can, thus, occur in two different enantiomeric forms. The vasodilatory effect of the S form is stronger than the vasodilatory effect of the R form. However, both the S form and racemic mixtures of the S form and the R form can be used.

10

Pharmaceutically acceptable salts of felodipine can be prepared from inorganic and organic acids including for example acetic, benzene-sulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethonic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, and p-toluene-sulfonic acids.

15

An extended release formulation can, for example, be constructed to give a hydrophilic gel matrix wherein the active substance is enclosed and which upon contact with aqueous solutions will swell to permit release of the active substance by diffusion and/or attrition.

20

In order to prevent decomposition of ramipril substance by the action of moisture during storage or compression during the manufacturing process the substance is, according to the present invention preferably powder-coated when included in a compressed part of the dosage form. The dihydropyridine substance is light sensitive and is, therefore, protected by a coating layer.

25

The dose range of ramipril in the combined fixed unit dosage forms is 1-10 mg. The dose range in the combined fixed unit dosage forms is, for felodipine

30

1-10 mg, for nitrendipine 2-40 mg, for nifedipine 5-70 mg and for lacidipine 1-8 mg.

Most preferred dose range in the combined fixed unit dosage forms is, for ramipril  
5 1-5 mg, for felodipine 1-5 mg, for nitrendipine 5-20 mg, for nifedipine 10-60 mg and for lacidipine 2-6 mg.

A preferred form of the present invention consists of a solid fixed unit dosage form for oral administration which is a low dose combination of an instant release  
10 formulation of 1-5 mg of the long acting ACE inhibitor ramipril or a pharmaceutically acceptable salt thereof, and an extended release formulation of 1-5 mg of the vascular selective calcium antagonist felodipine or a pharmaceutically acceptable salt thereof. Especially preferred dose intervals for this preferred form of the invention are 1-3 mg of ramipril and 1-3 mg of felodipine. The preferred  
15 dosis quotient between ramipril and felodipine in the preferred form of the present invention is 1:1.

The pharmaceutical preparations of the present invention are for once daily administration utilizing the different blood pressure lowering mechanisms of the  
20 ACE inhibitor ramipril in an instant release formulation and a dihydropyridine compound selected from the group consisting of felodipine, nitrendipine, nifedipine, and lacidipine in an extended release formulation. The bioavailability of the ramipril component of the pharmaceutical preparation according to the present invention as measured by the blood plasma concentration of ramiprilat is  
25 equivalent to that of the same component administered separately, see Example 1. Also the bioavailability of the dihydropyridine component of the pharmaceutical preparation is equivalent as measured in the same way, see Example 2. The compositions of tablets which were tested are shown in Example 12.

30 The use of a low dose of the two active components and the extended release of

the dihydropyridine component of the pharmaceutical preparations of the present invention administered once daily give a lowering effect on blood pressure but no compensatory increase in heart rate. It is effective in the treatment of systolic as well as diastolic hypertension. The pharmaceutical preparation is particularly effective in the treatment of systolic hypertension. So administered the preparations have a beneficial influence upon conditions of and associated with high blood pressure (hypertension) in mammals including man. Examples 3 and 4 illustrate the effectiveness of the pharmaceutical preparations of the invention in comparative tests between either ramipril or felodipine and solid fixed combination dosage forms of ramipril and felodipine. It can be seen that there is a surprisingly high degree of reduction in the systolic and diastolic blood pressure of the combined low dose (2.5 mg + 2.5 mg of ramipril and felodipine) preparation in the example in comparison both with each of the components in monotherapy and with the fixed combined preparation of the components in higher (5 mg + 5 mg) dose. The incidence of the most common adverse events during administration of an ACE inhibitor (dizziness, headache, fatigue, nausea and coughing) are low and comparable with that of placebo. The adverse events of administration of dihydropyridine calcium antagonists (increased heart rate, flushing, peripheral oedema, headache and dizziness) are also low and comparable to placebo.

Above all it is evident from Examples 3 and 4 that the most bothersome adverse event of administration of ACE inhibitors, namely coughing, and of administration of dihydropyridine calcium antagonists, namely peripheral oedema and flushing is less common with the low dose combination compared with the monotherapies (F5 and R5).

The release of the respective components in in vitro tests can be seen in Examples 5 to 8.

The pharmaceutical preparation is formulated as a combined solid fixed unit

dosage form for oral administration which in combination with the once daily administration facilitates the regimen and improves patient compliance.

5 The combined solid fixed unit dosage forms of the present invention can be for example capsules or tablets, which optionally can be coated.

As examples of formulations of ramipril which can be enclosed into capsules can be mentioned ramipril in the form of powder or granules, optionally attached to a carrier substance, and tablets. Examples of extended release preparations of  
10 dihydropyridine which can be enclosed into such capsules are granules or tablets. A capsule wherein the ramipril substance is attached to a carrier substance and the dihydropyridine is enclosed in a tablet core consisting of a hydrophilic gel matrix and the process for manufacturing the same is illustrated in Example 9.

15 Examples of the construction of tablets as fixed unit dosage forms of ramipril and an extended release dihydropyridine portion are shown in Figure 1, 2 and 3.

Figure 1 illustrates a tablet where the dihydropyridine ER (D) matrix preparation is enclosed in a surrounding layer containing instant release ramipril (R)  
20 substance. Such a tablet can be manufactured in a suitable tableting machine. Alternatively, the matrix containing dihydropyridine can be compressed to tablets in a tableting machine and then coated with a coating containing ramipril. One tablet of this type is illustrated in Example 10.

25 Figure 2 illustrates a tablet where the ramipril (R) component is placed at the upper part of the matrix containing the dihydropyridine ER (D) preparation. The instant release ramipril component is contained in a smaller part which is enclosed in a larger, separate part containing the felodipine extended release preparation. Instant release of ramipril is achieved since it is not entirely enclosed in the  
30 matrix. Such a tablet can be manufactured in a suitable tableting machine.

Figure 3 illustrates a tablet which is composed of one tablet layer containing the instant release ramipril (R) substance joined to another tablet layer containing the dihydropyridine ER (D) preparation resulting in a multiple layer tablet. The two tablet layers can be joined directly to each other or via one or more intermediate layers (L).

### Example 1

Pharmacokinetics of ramiprilat on treatment day 7 following once daily administration of the present invention according to Example 12 and a free monotherapy ramipril tablet (B). both given at 5 mg dosages, in 18 healthy volunteers.  $C_{\max}$  is the peak plasma concentration,  $t_{\max}$  is the time after administration the peak concentration was attained.  $C_{\min}$  is the lowest plasma concentration during the period. AUC is the area under the plasma concentration curve. SD is the standard deviation. p-values greater than 0.05 mean that no statistical significance in the quotient or the difference is at hand.

	<u>Parameter</u>		<u>Treatment</u>		<u>Comparison</u>
			A	B	
20	$C_{\max}$ (nmol/l)	mean	23.8	24.2	A/B
		SD	13.8	12.2	p=0.57
	$t_{\max}$ (h)	mean	2.8	2.5	A-B
		SD	1.1	0.9	p=0.35
25	$C_{\min}$ (nmol/l)	mean	3.9	4.1	A-B
		SD	1.2	0.9	p=0.64
	AUC (nmol·h/l)	mean	211.1	213.3	A/B
		SD	54.7	45.3	p=0.94

**Example 2**

Pharmacokinetics of felodipine on treatment day 7 following once daily administration of the present invention according to Example 12 and a free monotherapy felodipin tablet (B), both given at 5 mg dosages, in 18 healthy volunteers.  $C_{\max}$  is the peak plasma concentration,  $t_{\max}$  is the time after administration the peak concentration was attained.  $C_{\min}$  is the lowest plasma concentration during the period. AUC is the area under the plasma concentration curve. SD is the standard deviation. p-values greater than 0.05 mean that no statistical significance in the quotient or the difference is at hand.

	<u>Parameter</u>		<u>Treatment</u>		<u>Comparison</u>
			A	B	
	$C_{\max}$ (nmol/l)	mean	2.8	3.2	A/B
		SD	1.0	1.3	p=0.18
15	$t_{\max}$ (h)	mean	4.6	4.6	A-B
		SD	1.9	2.6	p=0.91
	$C_{\min}$ (nmol/l)	mean	0.9	0.9	A-B
		SD	0.3	0.3	p=0.16
20	AUC (nmol·h/l)	mean	38.4	39.5	A/B
		SD	14.5	12.9	p=0.33

**Example 3**

The antihypertensive efficacy and tolerability of the combined fixed unit dosage form of felodipine ER and ramipril in doses of 5+5 mg and 2.5+2.5 mg were compared with those of individual monotherapies of felodipine ER 5 mg and ramipril 5 mg and with placebo in this double-blind, five armed parallel group multicentre study. Patients with primary hypertension whose supine diastolic blood pressure (DBP) was 95-110 mmHg inclusive at two separate occasions during the 4-6 week placebo run-in period were randomised to treatment either with

felodipine ER-ramipril 5+5 mg (FR 5+5), felodipine ER-ramipril 2.5+2.5 mg (FR 2.5+2.5), felodipine ER 5 mg (F5), ramipril 5 mg (R5), or placebo.

- Eleven-hundred and three (1103) patients were enrolled and nine-hundred and thirty-nine (939) patients from six countries (Australia, Canada, Denmark, Italy, New Zealand and Sweden) were randomised into this study. Eight-hundred and seventy (870) patients completed the study. In the analyses 518 males and 421 females with a mean age of 57 years, ranging from 24 to 86 years, were included.
- Supine diastolic blood pressure (DBP) and supine systolic blood pressure (SBP) were measured 4 hours and 24 hours post dose at randomisation (baseline) and after 11 and 12 weeks of treatment.

Mean reduction in supine DBP and SBP from baseline to average of 11 and 12 weeks treatment (p-values less than 0.05 are statistically significant.)

Supine DBP (mm Hg)

Administered agent	4 hours	24 hours
Placebo	-6.5	-5.9
FR 2.5+2.5	-12.4	-10.1
FR 5+5	-14.0	-11.5
F5	-11.4	-9.4
R5	-8.9	-7.6

Supine SBP (mm Hg)

Administered agent		4 hours	24 hours
5	Placebo	-6.8	-5.6
	FR 2.5+2.5	-17.9	-14.2
	FR 5+5	-20.1	-14.8
	F5	-13.3	-11.9
	R5	-12.1	-8.6

10

All active treatments gave a statistically significant reduction in supine DBP (24 hours and 4 hours post dose) from baseline to the average of 11 to 12 weeks of treatment compared with placebo.

15 Mean differences in change (from baseline to average 11 to 12 weeks) in blood pressure. Comparison between combination treatments and placebo.

Comparison	Supine DBP		Supine SBP		
	24-hr p-value	4-hr p-value	24-hr p-value	4-hr	p-value
20	<hr/>				
	FR 2,5+2,5				
	vs placebo	-4.5 <0.001	-6.6 <0.001	-9.0 <0.001	-13.2 <0.001
25	FR 5+5				
	vs placebo	-6.0 <0.001	-8.0 <0.001	-9.6 <0.001	-15.0 <0.001

Both treatments with combined fixed unit dosage forms given once daily to hypertensive patients gave a statistically significant reduction in both supine systolic and diastolic blood pressure compared to placebo, both at peak (4 hours post dose intake) and at trough (24 hours post dose intake).

30



Mean differences in change (from baseline to average 11 to 12 weeks) in supine blood pressure. Comparison between treatments

5	Comparison	Supine DBP		Supine SBP		
		24-hr p-value	4-hr p-value	24-hr p-value	4-hr	p-value
10	FR 5+5					
	vs F5	-1.9 0.015	-2.8 0.004	-1.9 0.198	-7.3	<0.001
	FR 5+5					
	vs R5	-3.9 <0.001	-5.7 <0.001	-6.9 <0.001	-8.5	<0.001
15	FR 2.5+2.5					
	vs F5	-0.4 0.617	-1.3 0.166	-1.3 0.379	-5.5	0.001
	FR 2.5+2.5					
	vs R5	-2.4 0.003	-4.2 <0.001	-6.3 <0.001	-6.7	<0.001

The treatments with combined fixed unit dosage forms also gave a significantly greater reduction in both supine systolic and diastolic blood pressure than the individual monotherapies.

Furthermore, the low dose combination is equally (compared to felodipine) or more (compared to ramipril) effective in reducing supine diastolic and systolic blood pressure than double the dose of the individual monotherapies.

Similar results were obtained in the standing position indicating no orthostatic effects with any of the treatments.

Most common adverse events (% of patients)

	N=187	N=186	N=190	N=188	N=188
	Plac	FR2.5+2.5	FR5+5	F5	R5
5					
Headache	9.1	5.9	7.4	6.9	5.9
Dizziness	5.3	4.3	3.2	5.3	6.4
Fatigue	1.6	1.1	2.6	<1.0	3.2
Nausea	2.7	1.6	1.1	1.6	3.2
10 Oedema peripheral	3.7	3.8	4.7	5.9	1.6
Feeling warmth/Flush	<1.0	3.8	2.6	7.4	2.7
Coughing	2.7	5.9	7.4	4.8	10.6

Both therapies with combined fixed unit dosage forms were very well tolerated.

- 15 The number of patients with adverse events and number of patients with adverse events causing stop of therapy in the fixed combination groups were comparable to that of placebo.

- 20 The incidence of the most common adverse event observed during administration of an ACE inhibitor (dizziness, headache, fatigue, nausea and coughing) and during administration of dihydropyridine calcium antagonists (increased heart rate, flushing, peripheral oedema, headache and dizziness) tended to be lower during therapy with combined fixed unit dosage forms than during therapy with the individual monotherapies. Above all, this is evident for the most bothersome
- 25 adverse events with ACE inhibitors coughing, and dihydropyridine calcium antagonists, peripheral oedema and flush.

**Example 4**

- 30 Result of a clinical study evaluating efficacy and tolerability of a combined fixed unit dosage form of felodipine ER and ramipril in the dose 2.5 + 2.5 mg (FR

2.5+2.5) in comparison with the individual monotherapies ramipril 2.5 mg (R 2.5) and felodipine ER 2.5 mg (F 2.5) given once daily. The study was double-blind, multicentre, 3-armed parallel group design. Similar inclusion criteria as the study of Example 1 and treatment length 12 weeks. About 600 patients completed the study. Results of measurement of blood pressures 24 hours post administration.

Mean reduction in supine DBP and SBP from baseline to 12 weeks (Pressures in mm Hg). Supine BP measured at 24 hours.

10	<u>Administered agent</u>	<u>Supine DBP</u>	<u>Supine SBP</u>
	FR 2.5+2.5	-12.0	-15.5
	F 2.5	-9.6	-12.0
	R 2.5	-9.8	-11.3

15 Adjusted mean difference in change from baseline to 12 weeks. Supine BP measured at 24 hours.

20	<u>Comparison</u>	<u>Supine DBP</u>		<u>Supine SBP</u>	
		<u>24 hr</u>	<u>p-value</u>	<u>24 hr</u>	<u>p-value</u>
	FR 2.5+2.5 vs F2.5	-2.4	0.01	-4.0	0.02
	FR 2.5+2.5 vs R2.5	-1.6	0.07	-3.9	0.02

Most common ADEs (% of patients)

		N = 216	N = 213	N = 213
		<u>FR 2.5 + 2.5</u>	<u>F 2.5</u>	<u>R 2.5</u>
5	Headache	5.1	5.6	4.2
	Back pain	3.7	3.8	6.6
	Coughing	6.0	1.4	5.2
	Vasodilatation	3.7	3.3	1.9
	Infection	1.9	3.3	2.3
10	Peripheral oedema	2.3	3.8	0.9
	Dizziness	2.3	1.9	2.3

**Example 5**

- 15 Capsule containing ramipril 2.5 mg on a carrier and a felodipine 5.0 mg compressed unit. Ramipril is released quickly ("instant release") and felodipine is released during an extended period ("extended release").

20 Dissolution of ramipril/felodipine in vitro was tested in 500 ml of a 0.1 M phosphate buffer pH 6.5 with addition of 0.4 % of cetyl trimethyl ammonium bromide (CTAB). USP dissolution apparatus No. 2 (paddle) equipped with stationary baskets, operated at 100 rpm was used. Release figures, in per cent, denote average values and within brackets minimum - maximum values. 6 capsules were tested. For the composition of the capsule. see Example 9.

25

	<u>Time (h)</u>	<u>Ramipril</u>	<u>Felodipine</u>
	0.5	102 (100-103)	not determined
	1	not determined	11 (11-13)
	4	"	61 (58-64)
30	7	"	101 (99-104)

**Example 6**

Dissolution of ramipril/felodipine in vitro from a coated tablet containing 2.5 mg/5 mg respectively of the active substances tested in 500 ml of a 0.1 M phosphate buffer pH 6.5 with addition of 0.4% of cetyl trimethyl ammonium bromide (CTAB). USP dissolution apparatus No. 2 (paddle) equipped with stationary baskets, operated at 100 rpm, was used. Release figures in per cent, denote average value and within brackets minimum - maximum values. 6 tablets were tested. For the composition of the tablet, see Example 10.

10

<u>Time (h)</u>	<u>Ramipril</u>	<u>Felodipine</u>
0.5	103 (99-107)	not determined
1	not determined	9 (8-9)
4	"	53 (50-56)
15 7	"	90 (86-94)

**Example 7**

Dissolution of ramipril/felodipine in vitro from a layered tablet containing 2.5 mg/2.5 mg respectively of the active substances in 500 ml of a 0.1 M phosphate buffer pH 6.5 with addition of 0.4% of cetyl trimethyl ammonium bromide (CTAB). USP dissolution apparatus No. 2 (paddle) equipped with stationary baskets, operated at 100 rpm, was used. Release figures, in per cent, denote average value and figures within brackets denote minimum-maximum values. 6 tablets were tested. For the composition of the tested tablet, see Example 11.

30

	<u>Time (h)</u>	<u>Ramipril</u>	<u>Felodipine</u>
	0.5	97 (90-103)	not determined
	1	not determined	8 (6-9)
	4	"	54 (51-56)
5	7	"	92 (89-94)

### Example 8

Dissolution of ramipril/felodipine in vitro from a layered tablet containing 5 mg/5  
10 mg respectively of the active substances tested in 500 ml of a 0.1 M phosphate  
buffer pH 6.5 with addition of 0.4% of cetyl trimethyl ammonium bromide  
(CTAB). USP dissolution apparatus No. 2 (paddle) equipped with stationary  
baskets, operated at 100 rpm, was used. Release figures in per cent, denote  
average values and figures within brackets denote minimum-maximum values. 6  
15 tablets were tested. For the composition of the tested tablet, see Example 12.

	<u>Time (h)</u>	<u>Ramipril</u>	<u>Felodipine</u>
	0.5	94 (89-100)	not determined
	1	not determined	12 (12-13)
20	4	"	60 (58-61)
	7	"	95 (93-96)

### Example 9

25 Capsule containing ramipril 2.5 mg on a carrier and a felodipine 5.0 mg  
compressed unit. Ramipril is released quickly ("instant release") and felodipine is  
released during an extended period ("extended release").

30 The felodipine tablet core was constructed according to the hydrophilic gel matrix

principle described in "Hydrophilic Matrix Sustained Release Systems Based on Polysaccharide Carriers" by Colin D. Melia, in Critical Reviews in Therapeutic Drug Carrier Systems, 8(4): 395-421 (1991) in the following way: Two different granulating solutions (I and II) were prepared and the solutions were used for  
5 granulating the powder mass (III).

<u>Solution I</u>		<u>mg/tablet</u>
	Felodipine	5.00
	Polyoxyl 40 hydrogenated castor oil	12.50
10	Propyl gallate	0.060
	Ethanol	30.00
<u>Solution II</u>		
	Polyvinyl pyrrolidone	24.00
15	Ethanol	300.0
<u>Powders in granulate III</u>		
	Hydroxypropyl methylcellulose	200.00
	Sodium Aluminium silicate	94.00
20	Lactose	56.00
	Microcrystalline cellulose	6.00
	Hydroxypropyl methylcellulose	30.00
	Sodium stearyl fumarate	8.60
25	The powder mixture was moistened with Solution I while mixing to homogeneity. Then Solution II was added and mixing was continued until homogeneity. Drying of the granulate was performed in a drying oven.	

The dry granulate was milled using a Frewitt oscillating granulator. After milling  
30 the granulate was mixed with additionally 30 mg per tablet of hydroxypropyl

methyll cellulose (HPMC) until homogeneity and then lubricated with sodium stearyl fumarate. The final mixing was continued for 3 minutes. Compression was performed in a Korsch Pharmapress 100 with 7 x 13 punches (scored). Obtained tablet hardness measured over the longest axis was greater than 20 kP.

5

The ramipril carrier was manufactured in the following way:

Coating solution

	Ramipril	3.33 g
10	HPMC	10.00 g
	Acetic acid 0.01 M	200 g
	EtOH	200 g

Core

15	Non-Pareille inert core	210 g
	(According to USP monograph for "Sugar Spheres")	

Equipment

	Fluid bed (Wurster equipped),
20	Spray Nozzle: Schlick
	Insert tube diameter 50 mm, length 60 mm

The coating process resulted in beads having a ramipril content of 13.5 mg/g. One of the tablets from the above was filled in a hard gelatine capsules, size 00,  
25 together with 185 mg of the ramipril containing beads.



Properties of the obtained capsules

Capsule weight	747 mg
Felodipine content	5.0
Ramipril content	2.4 mg/capsule

5

**Example 10**

Tablet containing ramipril in the coat and felodipine in the tablet core. Ramipril is released instantly whereas felodipine is released during an extended period.

- 10 The felodipine tablet core was constructed according to the hydrophilic gel matrix principle (See reference example 7) in the following way: Two different granulating solutions (I and II) were made, and these were used to granulate the powder mass (III).

15	<u>Solution I</u>	<u>mg/tablet</u>
	Felodipine	5.00
	Polyoxyl 40 hydrogenated castor oil	5.00
	Propyl gallate	0.060
	Ethanol	30.00

20

Solution II

	Hydroxypropyl cellulose	10.00
	Ethanol	160.00

25 Powders III

	Hydroxypropyl methylcellulose	100.00
	Sodium Aluminium silicate	47.00
	Lactose	28.00
	Microcrystalline cellulose	3.00
30	Sodium stearyl fumarate	4.20

The powder mixture was moistured with Solution I while mixing to homogeneity. The Solution II was added and mixing continued to homogeneity. Drying of the granulate was performed in a drying oven.

- 5 The dry granulate was milled using a Frewitt oscillating granulator. After milling, the granulate was lubricated with sodium stearyl fumarate and the final mixing was continued for 3 minutes. Tableting was performed on a tableting machine using 9 mm circular concave punches. Obtained tablet hardness was approximately 7-8 kP measured with a Schleuniger hardness tester.

10

The felodipine tablets obtained according to the above were used as cores in a coating process applying a coating layer comprising ramipril and, as a binder, hydroxypropyl methyl cellulose (HPMC) 6 cps, dissolved in a mixture of alcohol and an acetic acid water solution.

15

The tablet cores were coated in the following way:

Coating solution

	Acetic acid sol. 0.01 M	200 g
20	Ethanol	200 g
	HPMC 6 cps	10 g
	Ramipril	3.46 g

Cores

25	Felodipine ER tablets 5mg, diameter 9 mm (1000 tablets)	206 g
----	--	-------

Equipment

Fluid bed (Wurster equipped)

Spray nozzle: Schlick

Insert tube diameter 50 mm, length 60 mm

5

The HPMC was dissolved in a mixture of the acetic acid water solution and the ethanol, then the ramipril powder was dissolved in this solution. The solution was sprayed onto the tablets using the equipment and under the conditions specified above. Coating may, alternatively, be performed in other conventional equipment,

10 e.g. Accela Coata or coating pans.

Properties of the obtained tablets

Tablet weight 216 mg/tablet

Felodipine content 4.9 mg/tablet

15 Ramipril content 2.4 mg/tablet

**Example 11**

Combined instant release ramipril and extended release felodipine layered tablets

2.5 mg/2.5 mg. Composition.

20

	Component	mg/tablet
	<u>Ramipril layer</u>	
	Ramipril	2.5
5	Hydroxypropyl methylcellulose	0.4
	Lactose	24.0
	Maize starch 1500	48.8
	Microcrystalline cellulose	24.0
	Sodium stearyl fumarate	$\leq 1.0$
10	Water purified	q.s.
	<u>Felodipine layer</u>	
	Felodipine	2.5
	Hydroxypropylcellulose	10.0
15	Hydroxypropyl methylcellulose	100
	Lactose	28.0
	Microcrystalline cellulose	3.0
	Polyoxyl 40 hydrogenated castor oil	2.5
	Propyl gallate	0.06
20	Sodium aluminium silicate	47.0
	Sodium stearyl fumarate	$\leq 6$
	Ethanol	q.s.

Coating layer

	Colour iron oxide	about 0.3
	Hydroxypropyl methylcellulose	7.4
	Paraffin	about 0.1
5	Polyethylene glycol	1.9
	Titanium dioxide	0.8
	Water purified	about 64

Ramipril was granulated with hydroxypropyl methylcellulose in purified water.

- 10 The dried material was classified and mixed with lactose, maize starch and microcrystalline cellulose. Final mixing was made with sieved sodium stearyl fumarate. The felodipine granulate was manufactured separately according to the procedure described in Example 8. The two granulates were then fed into a layer press equipped with two filling stations and compressed into tablets.

15

The tablets were finally coated with an outer coating layer using conventional equipment.

**Example 12**

20

Combined instant release ramipril and extended release felodipine layered tablets 5 mg/5 mg. Composition.

	Comp nent	mg/tablet
	<u>Ramipril layer</u>	
	Ramipril	5.0
5	Hydroxypropyl methylcellulose	0.9
	Lactose	23.5
	Maize starch 1500	46.8
	Microcrystalline cellulose	23.5
	Sodium stearyl fumarate	≤ 1.0
10	Water purified	q.s.
	<u>Felodipine layer</u>	
	Felodipine	5.0
	Hydroxypropylcellulose	10.0
15	Hydroxypropyl methylcellulose	100.0
	Lactose	28.0
	Microcrystalline cellulose	3.0
	Polyoxyl 40 hydrogenated castor oil	5.0
	Propyl gallate	0.06
20	Sodium aluminium silicate	47.0
	Sodium stearyl fumarate	≤ 6
	Ethanol	q.s.
	<u>Coating layer</u>	
25	Colours, iron oxides	about 0.3
	Hydroxypropyl methylcellulose	7.5
	Paraffin	about 0.1
	Polyethylene glycol	1.9
	Titanium dioxide	0.8
30	Water purified	about 65

For the manufacturing process see example 11.

**Claims**

1. A pharmaceutical preparation for oral administration comprising a combination of
- 5 a) the ACE inhibitor ramipril, or a pharmaceutically acceptable salt thereof and,
- b) a dihydropyridine compound selected from the group consisting of felodipine, nitrendipine, nifedipine, and lacidipine, or a pharmaceutically acceptable salt
- 10 thereof
- characterized by
- 1) ramipril being in instant release form
- 15 2) the dihydropyridine compound being in extended release (ER) form
- 3) the combination being in a solid fixed unit dosage form.
2. A pharmaceutical preparation according to claim 1 wherein the dihydropyridine compound is felodipine.
- 20 3. A pharmaceutical preparation according to claim 1 wherein the dihydropyridine compound is nitrendipine.
4. A pharmaceutical preparation according to claim 1 wherein the dihydropyridine compound is nifedipine.
- 25 5. A pharmaceutical preparation according to claim 1 wherein the dihydropyridine compound is lacidipine.
- 30 6. A pharmaceutical preparation according to any of claims 1 to 5 wherein the



amount of ramipril or a pharmaceutically acceptable salt thereof is 1 to 10 mg and the amount of the dihydropyridine compound or a pharmaceutically acceptable salt thereof is 1 to 70 mg per dosage unit.

- 5     7. A pharmaceutical preparation according to any of claims 1 to 6 wherein the amount of ramipril or a pharmaceutically acceptable salt thereof is 1 to 5 mg and the amount of the dihydropyridine compound or a pharmaceutically acceptable salt thereof is 1 to 60 mg per dosage unit.
- 10    8. A pharmaceutical preparation according to claim 6 wherein the amount of each of ramipril or a pharmaceutically acceptable salt thereof and felodipine or a pharmaceutically acceptable salt thereof is 1-5 mg per dosage unit.
- 15    9. A pharmaceutical preparation according to claim 6 wherein the amount of each of ramipril or a pharmaceutically acceptable salt thereof and felodipine or a pharmaceutically acceptable salt thereof is 1-3 mg per dosage unit.
- 20    10. A pharmaceutical preparation according to claim 8 to 9 wherein the dosis quotient of the components is 1:1.
- 25    11. A pharmaceutical preparation according to any of claims 1 to 10 wherein the ER formulation is comprised in a hydrophilic gel matrix.
12. A pharmaceutical preparation according to any of claims 1 to 11 wherein the solid fixed unit dosage form is a capsule.
13. A pharmaceutical preparation according to any of claims 1 to 11 wherein the solid fixed unit dosage form is a tablet.
- 30    14. A pharmaceutical preparation according to any of claims 1 to 13 wherein the

ramipril component is included in a coating layer which is surrounding the dihydropyridine ER component.

15. A pharmaceutical preparation according to any of claims 13 or 14 wherein the dihydropyridine ER component is in a tablet layer which is joined to another tablet layer containing the ramipril component, or, optionally, wherein the dihydropyridine ER component is in a tablet layer which is joined, indirectly via one or more layers without active components, to another tablet layer containing the ramipril component.

10

16. A pharmaceutical preparation according to any of claims 1 to 11, 13 or 14 wherein one of the components is contained in a smaller part which is contained in a larger, separate part containing the other component.

17. A process for the manufacture of a pharmaceutical preparation according to any of claims 1 to 11 or 13 to 16 characterized in that the ramipril and the dihydropyridine ER components are compressed to a tablet in a tableting machine.

18. A process for the manufacture of a pharmaceutical preparation according to any of claims 1 to 11, 13, 15 or 16 characterized in that a tablet layer containing the ramipril component is joined to a tablet layer containing the dihydropyridine ER substance to produce a combined tablet.




19. A process according to any of claims 17 or 18 characterized in that the tablet product is coated with a pharmaceutically acceptable coating.

20. A process for the manufacture of a pharmaceutical preparation according to claim 12 characterized in that ramipril and an extended release form of dihydropyridine are enclosed into a capsule.

30

21. A pharmaceutical preparation according to any of claims 1 to 16 for use in the prevention or treatment of diseases in the cardiovascular system, in particular hypertension.
- 5     22. The use of a preparation according to any of claims 1 to 16 in the manufacture of a medicament intended for the treatment of diseases in the cardiovascular system.
- 10    23. A pharmaceutical preparation according to any of claims 1 to 16 for use in therapy.
- 15    24. A pharmaceutical preparation according to any of claims 1 to 16 for use in the prevention or treatment of diseases in the cardiovascular system, in particular hypertension in mammals including man.
- 20    25. A method of preventing or treating hypertension in mammals including man comprising the administration of an effective amount of a pharmaceutical preparation according to any of claims 1 to 16 to a patient in need of such treatment.
- 25    26. A method of preventing or treating hypertension in mammals including man comprising the administration once per day of an effective amount of a pharmaceutical preparation according to any of claims 1 to 16 to a patient in need of such treatment.
27. A method according to any of claims 25 or 26 wherein the pharmaceutical preparation is administered once daily.

1/1



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00972

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/22, A61K 38/05, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, WPIL, CLAIMS, MEDLINE, EMBASE, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Br J clin Pharmac, Volume 36, 1993, A.D. Bainbridge et al, "The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension" page 323 - page 330	1-10
A	--	11-24
X	Dialog Information Services, File 351, World Patent Index 81-95, Dialog accession no. C93-026534, WPI accession no. 93-059347/08, Polli G P: "Combined time-release calcium channel blocker and ACE inhibitor - used for treating hypertension, congestive heart failure and other coronary diseases", & CA, A, 2070085, 921201, 9308 (Basic)	1-24
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

- Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

13 December 1995

Date of mailing of the international search report

19.12.95

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00972

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5178867 A (GEORGE V. GUITTARD ET AL), 12 January 1993 (12.01.93), page 6, line 36 - line 68, claims  --	1-24
A	EP 0265685 A2 (HOECHST AKTIENGESELLSCHAFT), 4 May 1988 (04.05.88)  -- -----	1-24

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00972

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 25-27  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

30/10/95

International application No.  
PCT/SE 95/00972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 5178867	12/01/93	AU-A- 2544992	16/03/93
		CA-A- 2112679	04/03/93
		EP-A,B- 0600033	08/06/94
		FI-A,D- 940787	18/02/94
		JP-T- 6509809	02/11/94
		NO-A,D- 940376	07/02/94
		NZ-A- 244009	24/02/95
		PT-A- 100789	31/05/94
		WO-A- 9303711	04/03/93
		ZA-A- 9206241	04/10/93
EP-A2- 0265685	04/05/88	SE-T3- 0265685	
		AU-B,B- 611863	27/06/91
		AU-A- 7928087	14/04/88
		CA-A- 1317545	11/05/93
		DE-A- 3633496	14/04/88
		DE-A- 3780753	03/09/92
		ES-T- 2043626	01/01/94
		IE-B- 59975	04/05/94
		JP-A- 63096136	27/04/88
		NO-B,C- 175621	01/08/94
		US-A- 5098910	24/03/92